Legend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?

Simply Wall St.07-31

Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO. See our latest analysis ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655336101?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-31 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655336101","market":"nz","top_or_hot":-1,"title":"Legend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?","media":"Simply Wall St.","content":"<div>\n<p>Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO. See our latest analysis ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO. See our latest analysis ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s","article_id":"2655336101","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655336101","pubTimestamp":1785464509,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO.\nSee our latest analysis for Legend Biotech.\nLegend Biotech's share price has come under pressure despite its cell therapy focus, with the 30 day share price return down 34.04% and the 1 year total shareholder return down 51.24%, suggesting momentum has faded as investors reassess execution risk after the CEO change.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","LEGN":"传奇生物","XBI":"SPDR S&P Biotech ETF","CANC":"TEMA ONCOLOGY ETF","MEDI":"HARBOR HEALTH CARE ETF","BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF"},"translate_title":"传奇生物（LEGN）首席执行官离职引发质疑，该股还便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDI":0.6,"CANC":0.6,"LEGN":1.5,"XBI":1.5,"MEMS":0.6},"content_text":"Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO. See our latest analysis for Legend Biotech. Legend Biotech's share price has come under pressure despite its cell therapy focus, with the 30 day share price return down 34.04% and the 1 year total shareholder return down 51.24%, suggesting momentum has faded as investors reassess execution risk after the CEO change. If this leadership shake up has you reviewing your biotech exposure, it could be a good moment to look across the sector and see what else is moving through 41 healthcare AI stocks Legend Biotech still has a lead CAR T therapy, global partners and US$1.14b in revenue. However, the share price has dropped sharply after the CEO exit. Is this a strong business now offered at a mispriced level? AdvertisementMost Popular Narrative: 64.9% Undervalued At a last close of $19.05 against a narrative fair value of $54.23, Legend Biotech screens as heavily marked down, with that gap anchored in a detailed set of growth and margin assumptions that investors are now weighing against recent leadership changes.  Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE 5 and 6), and label updates that increase patient access, is setting up long-term revenue acceleration as the patient pool widens. Increasing international penetration with recent launches in multiple European and global markets, supported by ongoing manufacturing expansion and supply chain optimization, is expected to materially broaden Legend's total addressable market and improve gross and net margins as production scales.  Read the complete narrative. Want to see what sits behind that growth story for Legend Biotech? The narrative focuses on ambitious revenue compounding, margin expansion and a richer earnings profile that are framed as far from conservative. Result: Fair Value of $54.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Legend Biotech story also carries significant pressure points, including heavy reliance on CARVYKTI along with ongoing losses, with net income at a loss of US$250.1 million. Find out about the key risks to this Legend Biotech narrative. Next Steps With Legend Biotech sitting at the center of both concern and optimism, this is a good moment to review the data yourself and move quickly. To see both sides of the story in one place, take a closer look at the 3 key rewards and 1 important warning sign Looking for more Legend Biotech sized investment ideas? If this Legend Biotech update has you rethinking your watchlist, do not stop here. Use the Simply Wall Street Screener to uncover focused ideas that match your approach.  Spot potential mispricing early by scanning companies that currently appear out of favour through the 57 high quality undervalued stocks. Strengthen your downside protection by zeroing in on businesses highlighted in the 89 resilient stocks with low risk scores. Hunt for off-the-radar opportunities with solid fundamentals by checking the screener containing 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655336101","isCrawlerRequest":true}